JMIR Publications

ABSTRACT

Background:

Anxiety and depressive disorders affect hundreds of millions globally, with substantial barriers limiting access to evidence-based treatments like cognitive behavioral therapy (CBT). While digital mental health interventions (DMHIs) offer potential solutions to improve access to support, demonstrating evidence of efficacy is essential.

Objective:

Evaluate the efficacy of the Headspace Anxiety and Depression Program, a digitally delivered intervention grounded in the Unified Protocol (UP), a transdiagnostic treatment that integrated cognitive-behavioral and mindfulness-based strategies to target common drivers of emotional disorders, compared to a waitlist control group in reducing anxiety and depression symptoms and improving overall wellbeing.

Methods:

A fully remote, two-arm parallel-group randomized controlled trial was conducted with 168 participants (aged ≥18 years) who had clinically significant anxiety (GAD-7 ≥10) and/or depression symptoms (PHQ-8 ≥10). Participants were randomized to either the Headspace Anxiety and Depression Program (n=84) or waitlist control (n=84). The intervention consisted of 21 daily sessions delivered via the Headspace app. Primary outcomes were anxiety (GAD-7) symptoms and depression (PHQ-8). Secondary outcomes included sleep quality (PSQI), perceived stress (PSS-10), mindfulness (MAAS), and mental well-being (WEMWBS). Assessments were conducted at baseline, post-intervention, and 3-week follow-up using intention-to-treat analysis.

Results:

Retention was high (91.7%) with no serious adverse events reported. Significant group × time interactions were observed for both primary outcomes (P < .001). The Headspace group showed substantial reductions in anxiety symptoms [GAD-7: 34.5% reduction from baseline (11.9±2.8) to follow-up (7.8±2.3), η²p = 0.350] and depression symptoms [PHQ-8: 33.9% reduction from baseline (12.1±2.8) to follow-up (8.0±2.0), η²p = 0.370], while the control group remained stable. Combined anxiety and depression remission rates were significantly higher in the Headspace group (21.4%) versus controls (8.3%, P = .03), as were treatment response rates (27.3% vs 2.3%, P = .03). All secondary outcomes demonstrated significant improvements in the Headspace group, including sleep quality (30.2% increase), perceived stress (13.2% reduction), mindfulness (10.3% increase), and mental well-being (10.7% increase).

Conclusions:

The Headspace Anxiety and Depression Program demonstrated efficacy in reducing anxiety and depression symptoms and improving overall wellbeing. The intervention showed sustained benefits at a 3-week follow-up and significant improvements in remission and treatment response rates. Findings support the potential of evidence-based DMHIs to address barriers in mental healthcare delivery and provide accessible treatment options for individuals with anxiety and depression. Clinical Trial: ClinicalTrials.gov: NCT06434883